Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

PURPOSE: We describe the first-in-human dose-escalation trial for ALRN-6924, a stabilized, cell-permeating peptide that disrupts p53 inhibition by mouse double minute 2 (MDM2) and MDMX to induce cell-cycle arrest or apoptosis in TP53-wild-type (WT) tumors. PATIENTS AND METHODS: Two schedules were ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Saleh, Mansoor N., Patel, Manish R., Bauer, Todd M., Goel, Sanjay, Falchook, Gerald S., Shapiro, Geoffrey I., Chung, Ki Y., Infante, Jeffrey R., Conry, Robert M., Rabinowits, Guilherme, Hong, David S., Wang, Judy S., Steidl, Ulrich, Walensky, Loren D., Naik, Gurudatta, Guerlavais, Vincent, Vukovic, Vojislav, Annis, D. Allen, Aivado, Manuel, Meric-Bernstam, Funda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401461/
https://www.ncbi.nlm.nih.gov/pubmed/34301750
http://dx.doi.org/10.1158/1078-0432.CCR-21-0715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401461/
https://www.ncbi.nlm.nih.gov/pubmed/34301750
http://dx.doi.org/10.1158/1078-0432.CCR-21-0715

Ejemplares similares